Evidence map›Paper›PMID 35734436›Full record

ArticleFrontiers in genetics2022

Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation

Dolores Gallardo-Rincón, Edgar Montes-Servín, Gabriela Alamilla-García, Elizabeth Montes-Servín, Antonio Bahena-González, Lucely Cetina-Pérez, Flavia Morales Vásquez, Claudia Cano-Blanco, Jaime Coronel-Martínez, Ernesto González-Ibarra and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Landscape of germlineFrontiers in oncology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Dolores Gallardo-RincónOvarian and Endometrial Cancer Program (COE), Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Edgar Montes-ServínOvarian and Endometrial Cancer Program (COE), Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Gabriela Alamilla-GarcíaOvarian and Endometrial Cancer Program (COE), Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Elizabeth Montes-ServínOvarian and Endometrial Cancer Program (COE), Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Antonio Bahena-GonzálezOvarian and Endometrial Cancer Program (COE), Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Lucely Cetina-PérezDepartment of Clinical Research and Medical Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Flavia Morales VásquezDepartment of Medical Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Claudia Cano-BlancoDepartment of Medical Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Jaime Coronel-MartínezDepartment of Medical Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Ernesto González-IbarraOvarian and Endometrial Cancer Program (COE), Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Raquel Espinosa-RomeroOvarian and Endometrial Cancer Program (COE), Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Rosa María Alvarez-GómezDepartment of Clinical Research and Medical Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Abraham Pedroza-TorresHereditary Cancer Clinic, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Denisse Castro-EguiluzCervical Cancer Program (Micaela), Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Instituto Nacional de Cancerología · MXConsejo Nacional de Humanidades, Ciencias y Tecnologías · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BRCA mutationepithelial ovarian cancerlarge rearrangementsMexican founder mutationprogression-free survival

Identifiers

PMID35734436
PMCPMC9207274
OpenAlexW4281702465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.